AUDENTES THERAPEUTICS, INC. (NASDAQ:BOLD) Files An 8-K Regulation FD Disclosure
Item7.01.
| Regulation FD Disclosure. |
Audentes Therapeutics, Inc. (the Company) plans to present the
information in the investor presentation attached hereto as
Exhibit 99.1 at the Cowen and Company 37th Annual Health Care
Conference onMarch 7, 2017.
The information furnished with this report, including
Exhibit99.1, shall not be deemed filed for purposes of Section18
of the Securities Exchange Act of 1934, as amended (the Exchange
Act), or otherwise subject to the liabilities of that section,
nor shall it be deemed incorporated by reference into any other
filing under the Exchange Act or the Securities Act of 1933, as
amended, except as expressly set forth by specific reference in
such a filing.
| Item9.01 | Financial Statements and Exhibits. |
|
Exhibit Number |
Description |
|
| 99.1 | Investor Presentation. |
2
About AUDENTES THERAPEUTICS, INC. (NASDAQ:BOLD)
Audentes Therapeutics, Inc. is an early-stage biotechnology company. The Company is focused on developing and commercializing gene therapy products for patients suffering from serious, life-threatening rare diseases caused by single gene defects. The Company has a portfolio of product candidates, including AT132 for the treatment of X-Linked Myotubular Myopathy (XLMTM); AT342 for the treatment of Crigler-Najjar Syndrome (Crigler-Najjar); AT982 for the treatment of Pompe disease, and AT307 for the treatment of the CASQ2 subtype of Catecholaminergic Polymorphic Ventricular Tachycardia (CASQ2-CPVT). The Company’s subsidiary is Audentes Therapeutics UK Ltd. As of September 30, 2016, the Company had not generated any revenues. AUDENTES THERAPEUTICS, INC. (NASDAQ:BOLD) Recent Trading Information
AUDENTES THERAPEUTICS, INC. (NASDAQ:BOLD) closed its last trading session 00.00 at 15.43 with 25,522 shares trading hands.
